Industries · Precision Medicine
Precision medicine depends on robust molecular stratification. OMICS4 runs the multi-omics data generation behind patient subtyping and biomarker validation for research-use applications, via our in-house platforms.
Platforms used in this field
Overview
OMICS4 generates the data behind stratification studies: genomic, transcriptomic and protein-level, from blood, FFPE and fresh-frozen tissue. Multi-site collections are consolidated into one registered batch, processed under one chain of custody.
Platforms
Exome, targeted panels and whole genome across the cohort.
Bulk and single-cell expression profiling.
Protein panels for orthogonal measurement.
One documented protocol applied to every sample.
Whole blood, plasma, FFPE blocks and slides, fresh-frozen tissue and extracted nucleic acid. Criteria are published per sample type, for DNA and for RNA, including what is accepted from FFPE.
Cohort collections arriving from several sites are consolidated into one registered batch, so a difference between sites does not become a difference between runs. A cohort that enrols over time is processed batch by batch under the same documented protocol, with batch composition recorded so it can be accounted for at analysis.
A QC report for every sample. Sequencing files and, where the service covers it, aligned and quantified outputs. Result tables for PCR and protein work. Exports in the formats your team already imports, and turnaround published per service.
Analysis, integration, biomarker discovery and modelling are not part of a platform booking. They are run by GenXMap’s computational team. Ask for them in the quote request and both are scoped together.
Analysis at GenXMapHave a project in this space?